PURPOSE OF REVIEW: The chronic kidney disease (CKD) mineral bone disorder syndrome encompasses a number of metabolic, bone as well as vascular abnormalities of which vascular calcification is a prominent feature. Several noninvasive imaging techniques provide physicians with useful prognostic information beyond traditional cardiovascular and CKD-specific risk factors. We review the most recent evidence on vascular calcification screening as a tool for risk stratification in CKD patients. RECENT FINDINGS: Cardiovascular aging is accelerated and is associated with a poor prognosis in CKD patients. Numerous traditional and nontraditional risk factors have been associated with this outcome. Imaging markers and serological risk factors do not carry the same prognostic information. In fact, whereas serum biomarkers reflect the risk to which the individual is exposed at the time of measurement, imaging markers represent the cumulative result of prolonged exposure to one or multiple risk factors. As such, they have often been demonstrated to be better outcome predictors than serological markers. In some cases, imaging markers have been suggested as desirable targets of therapy or to guide treatment individualization. SUMMARY: Recent evidence suggests that cardiovascular imaging allows for cardiovascular risk stratification and treatment individualization in CKD patients.
PURPOSE OF REVIEW: The chronic kidney disease (CKD) mineral bone disorder syndrome encompasses a number of metabolic, bone as well as vascular abnormalities of which vascular calcification is a prominent feature. Several noninvasive imaging techniques provide physicians with useful prognostic information beyond traditional cardiovascular and CKD-specific risk factors. We review the most recent evidence on vascular calcification screening as a tool for risk stratification in CKDpatients. RECENT FINDINGS: Cardiovascular aging is accelerated and is associated with a poor prognosis in CKDpatients. Numerous traditional and nontraditional risk factors have been associated with this outcome. Imaging markers and serological risk factors do not carry the same prognostic information. In fact, whereas serum biomarkers reflect the risk to which the individual is exposed at the time of measurement, imaging markers represent the cumulative result of prolonged exposure to one or multiple risk factors. As such, they have often been demonstrated to be better outcome predictors than serological markers. In some cases, imaging markers have been suggested as desirable targets of therapy or to guide treatment individualization. SUMMARY: Recent evidence suggests that cardiovascular imaging allows for cardiovascular risk stratification and treatment individualization in CKDpatients.
Authors: An S De Vriese; Rogier Caluwé; Lotte Pyfferoen; Dirk De Bacquer; Koen De Boeck; Joost Delanote; Didier De Surgeloose; Piet Van Hoenacker; Bruno Van Vlem; Francis Verbeke Journal: J Am Soc Nephrol Date: 2019-11-08 Impact factor: 10.121
Authors: Liam Timms; Tianyi Zhou; Yue Lyu; Ju Qiao; Vishala Mishra; Rita Maria Lahoud; Gayatri Veeramani Jayaraman; Andrew S Allegretti; David Drew; Ravi T Seethamraju; Mukesh Harisinghani; Srinivas Sridhar Journal: Abdom Radiol (NY) Date: 2021-03-05
Authors: Antonio Bellasi; Luca Di Lullo; Domenico Russo; Roberto Ciarcia; Michele Magnocavallo; Carlo Lavalle; Carlo Ratti; Maria Fusaro; Mario Cozzolino; Biagio Raffaele Di Iorio Journal: J Clin Med Date: 2021-01-20 Impact factor: 4.241
Authors: Mieke J Peeters; Jan Ajg van den Brand; Arjan D van Zuilen; Yelka Koster; Michiel L Bots; Marc G Vervloet; Peter J Blankestijn; Jack Fm Wetzels Journal: J Nephrol Date: 2016-03-22 Impact factor: 3.902